Muthusamy RPh - ANI Pharmaceuticals COO RD

ANI Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0125 % which means that it generated a profit of $0.0125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.016) %, meaning that it created substantial loss on money invested by shareholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/17/2025, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.06. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 02/17/2025, Liabilities And Stockholders Equity is likely to grow to about 1.1 B, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.

Similar Executives

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota. ANI Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 601 people. ANI Pharmaceuticals (ANIP) is traded on NASDAQ Exchange in USA. It is located in 210 Main Street West, Baudette, MN, United States, 56623 and employs 642 people. ANI Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

ANI Pharmaceuticals Leadership Team

ANI Stock Performance Indicators

Additional Tools for ANI Stock Analysis